Please enable JavaScript to continue using this application.

Compare $CABA vs $PRLD | Chartloom

Compare

$CABA vs $PRLD

Cabaletta Bio Inc · Prelude Therapeutics Inc

CABA

Cabaletta Bio Inc

PRLD

Prelude Therapeutics Inc

Compare $CABA vs $PRLD

Comparing Cabaletta Bio Inc and Prelude Therapeutics Inc

CABACabaletta Bio Inc

PRLDPrelude Therapeutics Inc

CABACabaletta Bio Inc

Market cap

$315M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-12.7%

52W performance

-19.9%

FCF yield

-49.0%

PRLDPrelude Therapeutics Inc

Market cap

$310M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.94x

Rev growth (TTM)

—

YTD performance

42.5%

52W performance

173.9%

FCF yield

-10.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CABA

PRLD

Detailed metrics comparison

CABA

Cabaletta Bio Inc

PRLD

Prelude Therapeutics Inc

Market Cap

CABA$315M

PRLD$310M

Enterprise Value

CABA$110M

PRLD$284M

Price

CABA$1.93

PRLD$3.89

P/E Ratio

CABAN/A

PRLDN/A

P/S Ratio

CABA0.00x

PRLD13.82x

EV/Sales

CABA0.00x

PRLD12.64x

EV/EBITDA

CABA0.00x

PRLD0.00x

P/B Ratio

CABA1.61x

PRLD2.19x

P/FCF Ratio

CABAN/A

PRLDN/A

EV/FCF

CABA-0.71x

PRLD-8.53x

PEG Ratio

CABAN/A

PRLDN/A

Forward P/E (NTM)

CABAN/A

PRLDN/A

Forward P/S (NTM)

CABAN/A

PRLD5.94x

Revenue (TTM)

CABA$0

PRLD$22M

Revenue Growth (YoY)

CABAN/A

PRLDN/A

Forward Rev Growth

CABA452.2%

PRLD-14.3%

Gross Margin (TTM)

CABA0.0%

PRLD0.0%

Operating Margin (TTM)

CABA0.0%

PRLD0.0%

EBITDA Margin (TTM)

CABA0.0%

PRLD-293.5%

Net Margin (TTM)

CABA0.0%

PRLD-269.7%

FCF Margin (TTM)

CABAN/A

PRLD-148.3%

Net Income (TTM)

CABA$-181M

PRLD$-60M

FCF (TTM)

CABA$-154M

PRLD$-33M

EPS (TTM)

CABA-$1.20

PRLD-$0.61

ROE (TTM)

CABA-12827.0%

PRLD-7535.0%

ROA (TTM)

CABA-9547.0%

PRLD-4439.0%

ROIC (TTM)

CABA-11070.0%

PRLD-7535.0%

Cash

CABA$225M

PRLD$26M

Debt

CABA$20M

PRLD$0

Net Cash/Debt

CABA$205M

PRLD$26M

Current Ratio (TTM)

CABA5.79x

PRLD4.07x

Quick Ratio (TTM)

CABA5.64x

PRLD3.99x

Debt/Equity (TTM)

CABA0.09x

PRLD0.00x

Debt/Assets (TTM)

CABA0.0%

PRLD0.0%

Interest Coverage (TTM)

CABAN/A

PRLDN/A

Net Debt/EBITDA (TTM)

CABA0.00x

PRLD0.00x

Beta

CABA3.54

PRLD1.19

52W Performance

CABA-19.9%

PRLD173.9%

YTD Performance

CABA-12.7%

PRLD42.5%

% from 52W High

CABA-54.4%

PRLD-43.0%

% from 52W Low

CABA5.5%

PRLD238.3%

Asset Turnover (TTM)

CABA0.00x

PRLD0.16x

FCF Yield (TTM)

CABA-49.0%

PRLD-10.7%

Earnings Yield (TTM)

CABA-57.6%

PRLD-19.5%

Dividend Yield (TTM)

CABAN/A

PRLDN/A

Rule of 40

CABA0.0

PRLD-148.3

EV/GP/RG

CABAN/A

PRLDN/A

Ticker research

View CABA research View PRLD research

Metric	CABA Cabaletta Bio Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$315M	$310M
Enterprise Value	$110M	$284M
Price	$1.93	$3.89
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	13.82x
EV/Sales	0.00x	12.64x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.61x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.71x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.94x
Revenue & Growth
Revenue (TTM)	$0	$22M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	452.2%	-14.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-293.5%
Net Margin (TTM)	0.0%	-269.7%
FCF Margin (TTM)	N/A	-148.3%
Net Income (TTM)	$-181M	$-60M
FCF (TTM)	$-154M	$-33M
EPS (TTM)	-$1.20	-$0.61
ROE (TTM)	-12827.0%	-7535.0%
ROA (TTM)	-9547.0%	-4439.0%
ROIC (TTM)	-11070.0%	-7535.0%
Financial Health
Cash	$225M	$26M
Debt	$20M	$0
Net Cash/Debt	$205M	$26M
Current Ratio (TTM)	5.79x	4.07x
Quick Ratio (TTM)	5.64x	3.99x
Debt/Equity (TTM)	0.09x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.54	1.19
52W Performance	-19.9%	173.9%
YTD Performance	-12.7%	42.5%
% from 52W High	-54.4%	-43.0%
% from 52W Low	5.5%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.16x
FCF Yield (TTM)	-49.0%	-10.7%
Earnings Yield (TTM)	-57.6%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-148.3
EV/GP/RG	N/A	N/A
Ticker research	View CABA research	View PRLD research

Valuation

P/S Ratio

CABA

0.00x

PRLD

13.82x

EV/FCF

PRLD

-8.53x

CABA

-0.71x

Growth & revenue

Forward Revenue Growth

CABA

452.2%

PRLD

-14.3%

Profitability & performance

Gross Margin

CABA

0.0%

PRLD

0.0%

ROE

PRLD

-7535.0%

CABA

-12827.0%

FCF Yield %

PRLD

-10.7%

CABA

-49.0%

52-Week Performance

PRLD

173.9%

CABA

-19.9%

Detailed metrics comparison

CABA

Cabaletta Bio Inc

PRLD

Prelude Therapeutics Inc

Market Cap

CABA$315M

PRLD$310M

Enterprise Value

CABA$110M

PRLD$284M

Price

CABA$1.93

PRLD$3.89

P/E Ratio

CABAN/A

PRLDN/A

P/S Ratio

CABA0.00x

PRLD13.82x

EV/Sales

CABA0.00x

PRLD12.64x

EV/EBITDA

CABA0.00x

PRLD0.00x

P/B Ratio

CABA1.61x

PRLD2.19x

P/FCF Ratio

CABAN/A

PRLDN/A

EV/FCF

CABA-0.71x

PRLD-8.53x

PEG Ratio

CABAN/A

PRLDN/A

Forward P/E (NTM)

CABAN/A

PRLDN/A

Forward P/S (NTM)

CABAN/A

PRLD5.94x

Revenue (TTM)

CABA$0

PRLD$22M

Revenue Growth (YoY)

CABAN/A

PRLDN/A

Forward Rev Growth

CABA452.2%

PRLD-14.3%

Gross Margin (TTM)

CABA0.0%

PRLD0.0%

Operating Margin (TTM)

CABA0.0%

PRLD0.0%

EBITDA Margin (TTM)

CABA0.0%

PRLD-293.5%

Net Margin (TTM)

CABA0.0%

PRLD-269.7%

FCF Margin (TTM)

CABAN/A

PRLD-148.3%

Net Income (TTM)

CABA$-181M

PRLD$-60M

FCF (TTM)

CABA$-154M

PRLD$-33M

EPS (TTM)

CABA-$1.20

PRLD-$0.61

ROE (TTM)

CABA-12827.0%

PRLD-7535.0%

ROA (TTM)

CABA-9547.0%

PRLD-4439.0%

ROIC (TTM)

CABA-11070.0%

PRLD-7535.0%

Cash

CABA$225M

PRLD$26M

Debt

CABA$20M

PRLD$0

Net Cash/Debt

CABA$205M

PRLD$26M

Current Ratio (TTM)

CABA5.79x

PRLD4.07x

Quick Ratio (TTM)

CABA5.64x

PRLD3.99x

Debt/Equity (TTM)

CABA0.09x

PRLD0.00x

Debt/Assets (TTM)

CABA0.0%

PRLD0.0%

Interest Coverage (TTM)

CABAN/A

PRLDN/A

Net Debt/EBITDA (TTM)

CABA0.00x

PRLD0.00x

Beta

CABA3.54

PRLD1.19

52W Performance

CABA-19.9%

PRLD173.9%

YTD Performance

CABA-12.7%

PRLD42.5%

% from 52W High

CABA-54.4%

PRLD-43.0%

% from 52W Low

CABA5.5%

PRLD238.3%

Asset Turnover (TTM)

CABA0.00x

PRLD0.16x

FCF Yield (TTM)

CABA-49.0%

PRLD-10.7%

Earnings Yield (TTM)

CABA-57.6%

PRLD-19.5%

Dividend Yield (TTM)

CABAN/A

PRLDN/A

Rule of 40

CABA0.0

PRLD-148.3

EV/GP/RG

CABAN/A

PRLDN/A

Ticker research

View CABA research View PRLD research

Metric	CABA Cabaletta Bio Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$315M	$310M
Enterprise Value	$110M	$284M
Price	$1.93	$3.89
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	13.82x
EV/Sales	0.00x	12.64x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.61x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.71x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.94x
Revenue & Growth
Revenue (TTM)	$0	$22M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	452.2%	-14.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-293.5%
Net Margin (TTM)	0.0%	-269.7%
FCF Margin (TTM)	N/A	-148.3%
Net Income (TTM)	$-181M	$-60M
FCF (TTM)	$-154M	$-33M
EPS (TTM)	-$1.20	-$0.61
ROE (TTM)	-12827.0%	-7535.0%
ROA (TTM)	-9547.0%	-4439.0%
ROIC (TTM)	-11070.0%	-7535.0%
Financial Health
Cash	$225M	$26M
Debt	$20M	$0
Net Cash/Debt	$205M	$26M
Current Ratio (TTM)	5.79x	4.07x
Quick Ratio (TTM)	5.64x	3.99x
Debt/Equity (TTM)	0.09x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.54	1.19
52W Performance	-19.9%	173.9%
YTD Performance	-12.7%	42.5%
% from 52W High	-54.4%	-43.0%
% from 52W Low	5.5%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.16x
FCF Yield (TTM)	-49.0%	-10.7%
Earnings Yield (TTM)	-57.6%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-148.3
EV/GP/RG	N/A	N/A
Ticker research	View CABA research	View PRLD research